Combination treatment with ACY-738 can augment the anti-tumor efficacy of anti-PD-1 and anti-PD-L1 monoclonal antibodies in an Eμ-TCL1 adoptive transfer murine model by activating the cytotoxic CD8+ T-cell phenotype in chronic lymphocytic leukemia [97]. Here, PDCD1 is linked to neoplasm.